Just weeks ago, we said one of the most oversold pharmaceutical stocks to buy for the long haul was AbbVie (SYM: ABBV). In fact, on January 14, the pharmaceutical giant was trading at about $172. Today, it’s up to $206.51 and could easily race higher.
|
Company: Even better, the company just declared a $1.64 quarterly dividend, which is payable on May 15 to shareholders of record as of April 15. |
Investors Alley
What Elon Musk doesn’t want investors to know
|
AbbVie said it generated $15.1 billion in sales and an adjusted profit of $2.16 a share. Sales, up 5.6% year over beat, beat forecasts for $14.83 billion. And while earnings sank 23%, they still topped expectations for $2.12. BigBear.ai's stock surged 412% in three months on AI and data plays for government agencies. But Mode Mobile helps consumers make money on their own data just by using your phone like you normally do. So when you use apps…Listen to music…Or just charge your phone…You can get paid. So while BigBear.ai helps the rich get richer, Mode is positioned to capitalize on the biggest trend in tech: user data value. The company has just locked in their Nasdaq ticker ($MODE) as the data revolution accelerates, but pre-IPO shares are still available at just $0.26 each (plus 100% bonus shares when you act today). Mode’s users have already saved and earned $325M+, and with partnerships with Walmart and Best Buy, the company looks to be just getting started. Don't miss out: Pre-IPO shares available at $0.26 with 100% bonus shares for early investors. In short, ABBV offers significant upside potential moving forward. |
Brownstone Research
Found this helpful? Share it with others.
Written by Ian Cooper